USPTO Examiner CHANG KYUNG SOOK - Art Unit 1613

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19210719ORAL SOLID DOSAGE FORMS COMPRISING CANNABINOIDSMay 2025January 2026Allow820YesNo
18818363TOPICAL COMPOSITION FOR IMPROVED HEALING OF OPEN WOUNDSAugust 2024April 2025Allow710YesNo
18659232PUTRESCINE TOPICAL BARRIER FORMULATIONMay 2024July 2025Allow1410NoNo
18624804Personal Care FormulationsApril 2024April 2025Allow1210NoNo
18435678EFLORNITHINE AND SULINDAC, FIXED DOSE COMBINATION FORMULATIONFebruary 2024March 2025Allow1310YesNo
18406793Cardiovascular ProsthesesJanuary 2024December 2025Abandon2320NoNo
18397626PROCESS OF MAKING NANOEMULSIONDecember 2023January 2025Allow1210NoNo
18525209MEBENDAZOLE POLYMORPH FOR TREATMENT AND PREVENTION OF TUMORSNovember 2023December 2025Abandon2521NoNo
183865602-BENZO-[3,4-B] QUINOLINO-{B,G]INDENO [1',2':3,4] FLUORENO-[1,2-D] OXONINE-5,11,16,21-TETRAONE AS AN ANTIMICROBIAL COMPOUNDNovember 2023March 2024Allow401NoNo
183865793-(4-BROMOPHENYL)-5-((2-ISOPROPYL-5-METHYLPHENOXY)METHYL)-1,2,4-OXADIAZOLE AS AN ANTI-CANCER AND ANTIMICROBIAL COMPOUNDNovember 2023August 2024Allow921NoNo
18383999OCULAR INFLAMMATION TREATMENT WITH STABILIZED DEXAMETHASONEOctober 2023February 2026Abandon2740NoNo
18493990COSMETIC COMPOSITIONS, KITS THEREOF, AND METHODS FOR MAKING AND USING THE SAMEOctober 2023June 2024Allow800YesNo
18282627METHOD OF TREATING INFECTED AND NONINFECTED BURN WOUNDSSeptember 2023February 2026Abandon2910NoNo
18547346HAIR COSMETICAugust 2023March 2026Abandon3110NoNo
18231599Hair and Scalp Compositions and Related Treatment MethodsAugust 2023February 2026Abandon3010NoNo
18365724TRANSDERMAL DELIVERY SYSTEM INCLUDING AN INTERFACE MEDIATORAugust 2023June 2025Allow2211YesNo
18275718SPHERULITE COMPOSITIONSAugust 2023March 2026Abandon3110NoNo
18274638WATER-IN-OIL MAKEUP COSMETIC COMPOSITION HAVING WATER RESISTANCE AND CLEANSING PROPERTIESJuly 2023January 2026Allow3010YesNo
18357927INTRANASAL DELIVERY OF OLANZAPINE BY PRECISION OLFACTORY DEVICEJuly 2023January 2025Abandon1810NoNo
18345029DPP-IV INHIBITOR COMBINED WITH A FURTHER ANTIDIABETIC AGENT, TABLETS COMPRISING SUCH FORMULATIONS, THEIR USE AND PROCESS FOR THEIR PREPARATIONJune 2023July 2024Abandon1310NoNo
18258256BIORESORBABLE SEALING POWDERJune 2023March 2026Allow3310YesNo
18336431Silk-Based Moisturizer Compositions and Methods ThereofJune 2023June 2025Allow2420NoNo
18334667PUTRESCINE TOPICAL BARRIER FORMULATIONJune 2023July 2024Abandon1310NoNo
18327267TOPICAL COMPOSITION COMPRISED OF COD LIVER OIL FOR TREATING WOUNDS AND SKIN DISORDERSJune 2023September 2024Allow1630YesNo
18327278TOPICAL COMPOSITION COMPRISED OF COD LIVER OIL FOR TREATING WOUNDS AND SKIN DISORDERSJune 2023September 2024Allow1530YesNo
18124128COMPOUND AND METHOD FOR TREATING DISEASES AND DISORDERSMarch 2023May 2025Abandon2630NoNo
18123268Fast Release Benzoic Acid In FeedMarch 2023July 2024Abandon1620NoNo
18121576STEROIDAL COMPOSITIONS AND METHOD OF MAKING AND USEMarch 2023July 2024Allow1720YesNo
18177720POLYGLUTAMIC ACID COMPOSITIONS AND METHODS OF USINGMarch 2023April 2025Allow2550YesNo
18115008TARGETED GASTROINTESTINAL TRACT DELIVERY OF PROBIOTIC ORGANISMS AND/OR THERAPEUTIC AGENTSFebruary 2023July 2024Abandon1710NoNo
18112635SKIN TREATMENT METHODS AND COMPOSITIONS FOR TRANSDERMAL DELIVERY OF ACTIVE AGENTSFebruary 2023February 2024Allow1220YesNo
18171070TASTE-MASKING ORAL FORMULATIONS OF FASUDILFebruary 2023July 2024Allow1740YesNo
18106684NATURAL POLYMER-BASED TISSUE ADHESIVE WITH HEALING-PROMOTING PROPERTIESFebruary 2023June 2024Allow1620NoNo
18106501EDGED CATAPLASM AND MANUFACTURING PROCESSFebruary 2023February 2026Allow3620YesNo
18007390BRIGHTENING COSMETIC COMPOSITION COMPRISING SODIUM PYRUVATE AS ACTIVE INGREDIENTJanuary 2023August 2025Allow3110YesNo
18149804FOOD GRADE WHITENING AGENTS AND USES THEREOFJanuary 2023May 2024Abandon1710NoNo
18002859ANTISEPTIC COMPOSITIONSDecember 2022March 2026Allow3930YesNo
18009020ADHESIVE TRANSPARENT MULTIFUNCTIONAL WOUND-COVERING MATERIAL AND MANUFACTURING METHOD THEREOFDecember 2022November 2025Abandon3510NoNo
18007503Powder Coating Composition and Substrate Coated With Such Powder Coating CompositionDecember 2022January 2026Allow3820NoNo
18056981TOPICAL COMPOSITION FOR IMPROVED HEALING OF OPEN WOUNDSNovember 2022August 2024Abandon2111NoNo
18055494EFLORNITHINE AND SULINDAC, FIXED DOSE COMBINATION FORMULATIONNovember 2022November 2023Allow1220NoNo
17984461Method To Improve The Health Of The Microbiome In A Human Gastrointestinal System And Multi-Chamber Probiotic Delivery Products ThereforNovember 2022December 2025Allow3720YesNo
17923076AN ANTIMICROBIAL COMPOSITION FOR TACKLING MALODOURNovember 2022May 2025Allow3110NoNo
17922825HYALURONIC ACID-BASED HYDROGEL USING PEPTIDE CROSSLINKING AGENT, AND METHOD FOR PRODUCING SAMENovember 2022February 2026Allow3911NoNo
17970160KIT AND NEW METHOD OF TREATMENT FOR SKIN BASAL CELL AND SQUAMOUS CELL CARCINOMAOctober 2022July 2023Allow811NoNo
17967470COMPOSITIONS AND METHODS FOR TREATMENT OF SKIN INFECTIONSOctober 2022July 2023Allow910NoNo
17962763COMPOSITIONS AND METHODS FOR TREATING HOT FLASHESOctober 2022July 2025Allow3430NoNo
17938613CBD SUNSCREEN FORMULATIONS AND USES THEREOFOctober 2022December 2025Abandon3810NoNo
17995270MAKEUP APPLICATION METHODSeptember 2022November 2025Allow3720NoNo
17950387COMPOSITION FOR PROMOTING HAIR THICKENING, COMPOSITION FOR SUSTAINING GROWTH PHASE IN HAIR CYCLE AND COMPOSITION FOR PROMOTING VEGF PRODUCTION, COMPOSITION FOR PROMOTING TRANSITION FROM RESTING PHASE TO GROWTH PHASE IN HAIR CYCLE AND COMPOSITION FOR PROMOTING FGF7 PRODUCTION, AND COMPOSITION FOR PROMOTING HAIR CYCLE NORMALIZATIONSeptember 2022August 2025Abandon3520NoNo
17939396POWDERED FORMULATIONS OF CROMOLYN SODIUM AND IBUPROFENSeptember 2022January 2024Abandon1610NoNo
17902646COSMETIC FORMULATIONSeptember 2022March 2024Abandon1930YesNo
17905616ORAL SOLID PREPARATIONSSeptember 2022September 2025Abandon3701NoNo
17799856ANTIMICROBIAL COMPOSITIONSAugust 2022March 2026Allow4320NoNo
17880586COSMETIC FORMULATIONAugust 2022October 2025Abandon3820NoYes
17877005Water-soluble Unidirectional Moisture Transport Traditional Chinese Medicine Facial Mask and Preparation thereofJuly 2022April 2024Allow2121YesNo
17876700DPP-IV INHIBITOR COMBINED WITH A FURTHER ANTIDIABETIC AGENT, TABLETS COMPRISING SUCH FORMULATIONS, THEIR USE AND PROCESS FOR THEIR PREPARATIONJuly 2022August 2023Abandon1210NoNo
17795553COMPOSITIONS FOR HEMORRHOID TREATMENTJuly 2022September 2025Abandon3810NoNo
17871111Personal Care Compositions Incorporating Natural Benefit Agents and Methods for the SameJuly 2022May 2025Abandon3440NoNo
17759302MEDICAMENT COMPRISING A COMBINATION OF AMNIOTIC MEMBRANE AND UMBILICAL CORD BLOOD SERUM FOR WOUND HEALINGJuly 2022July 2025Abandon3610NoNo
17868480BIOCIDE COMPOSITION AND METHODS OF USEJuly 2022July 2025Allow3610NoNo
17866876DOSING REGIMENS AND METHODS FOR TREATING CANCERJuly 2022August 2025Abandon3710NoNo
17758315ORAL SOLID CANNABINOID OIL COMPOSITION FOR TREATING GASTROINTESTINAL DISORDERSJuly 2022August 2024Allow2610NoNo
17854297CONTROLLED RELEASE CORE-SHELL PARTICLES AND SUSPENSIONS INCLUDING THE SAMEJune 2022July 2025Allow3731NoNo
17848981COMPOSITION FOR PREVENTING AND TREATING INFLAMMATORY BOWEL DISEASE INCLUDING PUER TEA EXTRACTJune 2022June 2025Allow3640YesYes
17782088ANTIMICROBIAL COMPOSITIONS AND METHODS OF USING THEREOFJune 2022August 2025Abandon3810NoNo
17831333TOPICAL COMPOSITION FOR HOMEOSTATIC DELIVERY OF NITRIC OXIDE AND USES THEREOFJune 2022June 2024Allow2420YesNo
17752915Antiseptic WipesMay 2022December 2025Allow4320NoNo
17751883COSMETIC PRODUCT COMPRISING A COSMETIC COMPOSITION CONTAINED IN AN APPLICATORMay 2022June 2024Abandon2520NoNo
17746713COMPOSITION OF TANNIC ACID AND VITAMIN D AND METHODS OF USEMay 2022October 2023Abandon1710NoNo
17746555METHOD FOR WHITENING SKIN USING COMPOSITION FOR SKIN WHITENINGMay 2022February 2025Allow3340YesNo
17744685PHARMACEUTICAL COMPOSITIONS OF BERBERINE WITH EPA AND DHA, AND METHODS THEREOFMay 2022November 2023Allow1820NoNo
17743537WET WIPES WITH A CELLULOSIC SUBSTRATE AND GENTLE LOTIONMay 2022December 2023Allow1920NoNo
17743529WET WIPES WITH A CELLULOSIC SUBSTRATE AND GENTLE LOTIONMay 2022January 2024Allow2020NoNo
17743895Personal Care FormulationsMay 2022December 2023Allow1920NoNo
17739246Hydrogel-Fabric Composite For Cosmetic ApplicationsMay 2022March 2024Abandon2210NoNo
17773497AQUEOUS OXIDIZING COMPOSITION COMPRISING AMINO ACIDSApril 2022August 2025Allow4011YesNo
17755408OIL-IN-WATER TYPE COMPOSITIONApril 2022June 2025Allow3820NoNo
17732162COMPOSITION AND METHOD FOR ODOR CONTROLApril 2022August 2023Allow1610NoNo
17730305STEROIDAL COMPOSITIONS AND METHOD OF MAKING AND USEApril 2022February 2023Allow1020NoNo
17728522ANTI-AGING AND SKIN TONE LIGHTENING COMPOSITIONS AND METHODS FOR SAMEApril 2022March 2025Abandon3440NoNo
17770204PERSONAL CARE COMPOSITION COMPRISING A SILICON GLYCANApril 2022July 2025Allow3911NoNo
17717868Personal Care CompositionApril 2022June 2023Allow1410NoNo
17766487ORAL CARE COMPOSITION COMPRISING CUTTLEFISH BONE POWDERApril 2022May 2025Abandon3810NoNo
17763396A PUNICA GRANATUM EXTRACT AND ITS COSMETIC USESMarch 2022October 2025Allow4221YesNo
17763236TREATMENT OF SKIN DISORDERS WITH TOPICAL COMBINATION COMPOSITIONS COMPRISING TAPINAROF AND AN ADDITIONAL AHR ACTIVATORMarch 2022May 2025Abandon3801NoNo
17761792COMPOSITIONS AND METHODS FOR RESTORING OR INCREASING TISSUE PERFUSIONMarch 2022March 2025Allow3610YesNo
17638713COMPOSITION, PROCESS AND KIT FOR SEMI-PERMANENT STRAIGHTENING AND CURLING OF KERATIN FIBERSFebruary 2022March 2025Abandon3610NoNo
17613448METHOD FOR STABILIZING HUMIDITY-SENSITIVE PHARMACEUTICAL SUBSTANCE AND STABILIZED PREPARATION THEREOFFebruary 2022February 2023Allow1530YesNo
17674728PRODUCING ATP AND IMPROVING MITOCHONDRIAL FUNCTION IN A MAMMAL USING A POLY-OXYGENATED METAL HYDROXIDEFebruary 2022April 2024Abandon2610NoNo
17666577COMPOSITION FOR STIMULATING MUSCLE GROWTH, REPAIR, AND MAINTENANCEFebruary 2022April 2023Allow1410NoNo
17666181COMPOSITIONS AND METHODS FOR TREATMENT OF SKIN INFECTIONSFebruary 2022August 2022Allow610YesNo
17632959HIGH PERFORMANCE ANTIMICROBIAL COMPOSITIONFebruary 2022March 2025Abandon3810NoNo
17586618DEFINED DOSE CANNABIS PODJanuary 2022May 2025Abandon4021NoNo
17627960Engineered biodegradable vascular bioprostheses and production process thereofJanuary 2022August 2025Abandon4311NoNo
17576675READY-TO-USE ESTHETIC COMPOSITIONSJanuary 2022March 2026Allow5060YesYes
17576202USE OF NUTRITIONAL COMPOSITIONS HAVING A LOW PROTEIN AMOUNTJanuary 2022April 2024Allow2720YesNo
17574511INTRANASAL DELIVERY OF OLANZAPINE BY PRECISION OLFACTORY DEVICEJanuary 2022April 2023Allow1510YesNo
17626106COMPOSITION FOR EXTERNAL APPLICATIONJanuary 2022August 2025Abandon4340YesNo
17624797PREBIOTIC COSMETIC COMPOSITIONS AND METHODS FOR THE PREPARATION THEREOFJanuary 2022September 2025Abandon4420NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner CHANG, KYUNG SOOK.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
20
Examiner Affirmed
15
(75.0%)
Examiner Reversed
5
(25.0%)
Reversal Percentile
37.6%
Lower than average

What This Means

With a 25.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
78
Allowed After Appeal Filing
14
(17.9%)
Not Allowed After Appeal Filing
64
(82.1%)
Filing Benefit Percentile
21.8%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 17.9% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner CHANG, KYUNG SOOK - Prosecution Strategy Guide

Executive Summary

Examiner CHANG, KYUNG SOOK works in Art Unit 1613 and has examined 724 patent applications in our dataset. With an allowance rate of 61.3%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 27 months.

Allowance Patterns

Examiner CHANG, KYUNG SOOK's allowance rate of 61.3% places them in the 21% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by CHANG, KYUNG SOOK receive 2.45 office actions before reaching final disposition. This places the examiner in the 71% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by CHANG, KYUNG SOOK is 27 months. This places the examiner in the 71% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +40.0% benefit to allowance rate for applications examined by CHANG, KYUNG SOOK. This interview benefit is in the 87% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 23.0% of applications are subsequently allowed. This success rate is in the 30% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 33.1% of cases where such amendments are filed. This entry rate is in the 48% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 93.3% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 68% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 64.9% of appeals filed. This is in the 45% percentile among all examiners. Of these withdrawals, 62.2% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.

Petition Practice

When applicants file petitions regarding this examiner's actions, 56.1% are granted (fully or in part). This grant rate is in the 58% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.1% of allowed cases (in the 50% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 0% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.